Особенности выбора терапии воспалительных заболеваний кишечника на фоне злокачественных новообразований

1. Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E et al. ECCO guidelines on inflammatory bowel disease and malignancies. J Crohns Colitis. 2023;17(6):827–54.

PMID: 36528797. https://doi.org/10.1093/ecco-jcc/jjac187

2. Клинические рекомендации. Язвенный колит. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская гастроэнтерологическая ассоциация. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 193_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/193_2 (дата обращения – 16.06.2025). (Clinical guidelines. Ulcerative colitis. Association of Coloproctologists of Russia, Russian Gastroenterological Association. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 193_2. URL: https://cr.minzdrav.gov.ru/preview-cr/193_2 (date of access – 16.06.2025) (In Russ.)).

3. Клинические рекомендации. Болезнь Крона. Общероссийская общественная организация «Ассоциация колопроктологов России», Российская гастроэнтерологическая ассоциация. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 176_2. Доступ: https://cr.minzdrav.gov.ru/preview-cr/176_2 (дата обращения – 16.06.2025). (Clinical guidelines. Crohn’s disease. Association of Coloproctologists of Russia, Russian Gastroenterological Association. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 176_2. URL: https://cr.minzdrav.gov.ru/preview-cr/176_2 (date of access – 16.06.2025) (In Russ.)).

4. Sands BE, Irving PM, Hoops T, Izanec JL, Gao L-L, Gasink C et al.; SEAVUE Study Group. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–11.

PMID: 35691323. https://doi.org/10.1016/S0140-6736(22)00688-2

5. Ghosh S, Feagan BG, Ott E, Gasink C, Godwin B, Marano C et al. Safety of ustekinumab in inflammatory bowel disease: Pooled safety analysis through 5 years in Crohn’s disease and 4 years in ulcerative colitis. J Crohns Colitis. 2024;18(7):1091–1101.

PMID: 38310565. PMCID: PMC11302965. https://doi.org/10.1093/ecco-jcc/jjae013

6. Danese S, Hanauer SB, Jairath V, Mihaly E, Vicente Lidón R, Ott E et al. P457. Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s disease and ulcerative colitis. 17th Congress of ECCO; February 16–19, 2022. URL: https://www.ecco-ibd.eu/publications/congress-abstracts/item/p457-long-term-cumulative-safety-of-ustekinumab-in-bionaive-patients-with-crohn-s-disease-and-ulcerative-colitis.html (date of access – 16.06.2025).

7. Long MD, Danese S, Ott E, Gasink C, Miao Y, Baker T et al. 14: Malignancies in patients treated with ustekinumab: Long-term pooled safety analysis in Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis through up to 5 years. Gastroenterology. 2022;162(7):S-5.

https://doi.org/10.1016/S0016-5085(22)60014-3

8. Hasan B, Tandon KS, Miret R, Khan S, Riaz A, Gonzalez A et al. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. J Gastroenterol Hepatol. 2022;37(6):1016–21.

PMID: 35191100. https://doi.org/10.1111/jgh.15806

9. Pang AS, Hudesman D, Chang S, Axelrad JE. Su1849: Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to ustekinumab. Gastroenterology. 2019;156(6):S-634–S-635.

https://doi.org/10.1016/S0016-5085(19)38486-0

10. Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk of cancer recurrence in patients with immune-mediated diseases with use of immunosuppressive therapies: An updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024;22(3):499–512.e6.

PMID: 37579866. PMCID: PMC10859547. https://doi.org/10.1016/j.cgh.2023.07.027

11. Pans J, Loftus EV, Lacerda AP, Peyrin- Biroulet L, Dhaens G, Panaccione R et al. 114: Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn’s disease: Results from a randomized phase 3 U-ENDURE maintenance study. Gastroenterología y Hepatología. 2023;46:90347.

http://dx.doi.org/10.1016/S0210-5705(23)00246-7

12. Massano A, Bertin L, Zingone F, Buda A, Visaggi P, Bertani L et al. Extraintestinal cancers in inflammatory bowel disease: A literature review. Cancers. 2023;15(15):3824.

PMID: 37568640. PMCID: PMC10417189. https://doi.org/10.3390/cancers15153824

13. Axelrad JE, Hashash JG, Itzkowitz SH. AGA clinical practice update on management of inflammatory bowel disease in patients with malignancy: Commentary. Clin Gastroenterol Hepatol. 2024;22(7):1365–72.

PMID: 38752967. https://doi.org/10.1016/j.cgh.2024.03.032

14. Mala A, Foteinogiannopoulou K, Koutroubakis IE. Solid extraintestinal malignancies in patients with inflammatory bowel disease. World J Gastrointest Oncol. 2021;13(12):1956–80.

PMID: 35070035. PMCID: PMC8713323. https://doi.org/10.4251/wjgo.v13.i12.1956